4-N-methylaminoindole | 85696-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-N-methylaminoindole
• 英文别名: 4-methylaminoindole；N-methyl-1H-indol-4-amine
• CAS: 85696-93-1
• 化学式: C₉H₁₀N₂
• mdl: MFCD12924156
• 分子量: 146.192
• InChiKey: FYOXZNFGZDHMLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-N-methylaminoindole 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 23.0h， 以75%的产率得到4-氨基-N-甲基吲哚
  参考文献：
  名称：

  4-烷基氨基吲哚的意外重排

  摘要：

  在沸腾的甲苯中存在10mol％的水合甲苯-对磺酸的情况下，4-烷基氨基吲哚以良好的产率重排为相应的1-烷基-4-氨基吲哚。

  DOI：

  10.1039/c39820001356
• 作为产物：
  描述：

  4-氨基吲哚 在 吡啶 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-N-methylaminoindole
  参考文献：
  名称：

  Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors

  摘要：

  An examination of several amine-substituted analogs of N-1-benzenesulfonylindoles reveals that although they bind at human 5-HT6 serotonin receptors with high affinity, they are likely to bind in a dissimilar manner. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.059

文献信息

• Protein kinase C modulators. Indolactams. 1. Efficient and flexible routes for the preparation of (-)-indolactam V for use in the synthesis of analogs
  作者：James Quick、Bijali Saha、Paul E. Driedger

  DOI：10.1016/s0040-4039(00)78433-4

  日期：1994.11

  Three syntheses of the protein kinase C activator, (-)-indolactam V, are described and are compared for their potential utility in the preparation of ILV analogs. In one route the 4-amino functionality is introduced regiospecifically during the construction of the indole portion and enantiomeric control is achieved by the alkylation of the amine with a triflate derived from d-valine. One of the routes

  描述了三种蛋白激酶C激活剂（-）-吲哚内酰胺V的合成方法，并比较了它们在制备ILV类似物中的潜在效用。在一种途径中，在吲哚部分的构建过程中区域特异性地引入4-氨基官能团，并且通过胺与衍生自d-缬氨酸的三氟甲磺酸酯的烷基化来实现对映体控制。一种途径提供了外消旋的ILV，通过首次报道的吲哚内酰胺拆分可从中获得（-）-ILV。
• SUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Barbay Joseph Kent

  公开号：US20090048295A1

  公开（公告）日：2009-02-19

  Substituted 5,6,7,8-tetrahydroquinoline derivatives, which are C5 a receptor modulators, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, immune and inflammatory diseases and conditions, are disclosed.

  揭示了含有5,6,7,8-四氢喹啉衍生物的C5a受体调节剂、含有这些衍生物的组合物，以及它们用于预防和治疗疾病和症状的方法，包括但不限于免疫和炎症性疾病和症状。
• Chemical Compound, Pharmaceutical Composition Thereof, and Use and Application Thereof
  申请人：Beijing Hanmi Pharm. Co., Ltd.

  公开号：US20200172529A1

  公开（公告）日：2020-06-04

  Provided are a pyrimidinyl amino compound having protein kinase inhibitor activity, and a pharmaceutical composition containing said compound; also provided are a use and application of said compound. What is provided is selected from a group consisting of the compound represented by formula (I), a stereoisomer thereof, a tautomer thereof, a pharmacologically acceptable salt thereof, a solvate thereof, and a prodrug thereof. The described compound has good inhibitory activity against the JAK family of kinases and the SYK family of kinases, and therefore may serve as a JAK inhibitor and SYK inhibitor, and is effective in use for the prevention or treatment of diseases related to the JAK and SYK families of kinases.

  提供了一种具有蛋白激酶抑制活性的嘧啶基氨基化合物，以及含有该化合物的药物组合物；还提供了该化合物的用途和应用。所提供的选择自化合物的一组，该组包括由式（I）表示的化合物、其立体异构体、其互变异构体、其药理学上可接受的盐、其溶剂合物和其前药。所描述的化合物对JAK家族激酶和SYK家族激酶具有良好的抑制活性，因此可作为JAK抑制剂和SYK抑制剂，并在预防或治疗与JAK和SYK家族激酶相关的疾病中发挥作用。
• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040077650A1

  公开（公告）日：2004-04-22

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the modulation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体调节相关疾病中的用途。
• BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS
  申请人：Jia Zhaozhong J.

  公开号：US20120142671A1

  公开（公告）日：2012-06-07

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

  本发明涉及公式I的化合物及其药学上可接受的盐、酯和前药，这些化合物是Syk激酶的抑制剂。本发明还涉及用于制备这些化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制Syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由Syk激酶活性介导的多种疾病，如非霍奇金淋巴瘤的方法。